



**CK Life Sciences Int'l. (Holdings) Inc.**

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8222)

# Better Health Better Life

Half-year Report 2007



*This half-year report 2007 (in both English and Chinese versions) (“Half-year Report”) has been posted on the Company’s website at <http://www.ck-lifesciences.com>. Shareholders who have chosen to rely on copies of the Company’s corporate communication (including but not limited to annual report, summary financial report (where applicable), half-year report, summary half-year report (where applicable), quarter report, notice of meeting, listing document, circular and proxy form) posted on the Company’s website in lieu of the printed copies thereof may request the printed copy of the Half-year Report.*

*Shareholders who have chosen to receive the corporate communication using electronic means through the Company’s website and who for any reason have difficulty in receiving or gaining access to the Half-year Report posted on the Company’s website will promptly upon request be sent the Half-year Report in printed form free of charge.*

*Shareholders may at any time choose to change your choice as to the means of receipt (i.e. in printed form or by electronic means through the Company’s website) and/or the language of the Company’s corporate communication by notice in writing to the Company’s Branch Share Registrar, Computershare Hong Kong Investor Services Limited at Rooms 1806 – 1807, 18th Floor, Hopewell Centre, 183 Queen’s Road East, Hong Kong.*

*Shareholders who have chosen to receive printed copy of the corporate communication in either English or Chinese version will receive both English and Chinese versions of this Half-year Report since both languages are bound together into one booklet.*

## **Characteristics of the Growth Enterprise Market (“GEM”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)**

***GEM has been established as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies may list on GEM with neither a track record of profitability nor any obligation to forecast future profitability. Furthermore, there may be risks arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.***

***Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.***

***The principal means of information dissemination on GEM is publication on the internet website operated by the Stock Exchange. Listed companies are not generally required to issue paid announcements in gazetted newspapers. Accordingly, prospective investors should note that they need to have access to the GEM website in order to obtain up-to-date information on GEM-listed issuers.***

*This document, for which the directors (the “Directors”) of CK Life Sciences Int’l., (Holdings) Inc. (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this document is accurate and complete in all material respects and is not misleading; (ii) there are no other matters the omission of which would make any statement in this document misleading; and (iii) all opinions expressed in this document have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

# Chairman's Statement

HK\$ Million	The First Half Results		
	2007	2006	Difference
Sales revenue	958.1	868.4	+10%
Investment proceeds	139.5	53.8	+159%
<b>Total revenue</b>	<b>1,097.6</b>	<b>922.2</b>	<b>+19%</b>
<b>Profit attributable to shareholders</b>	<b>66.2</b>	<b>14.8</b>	<b>+347%</b>

Maintaining the strong growth momentum recorded in the past few quarters, CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Group") has achieved a pleasing performance during the first half of 2007.

For the six months ended 30 June 2007, profit attributable to shareholders was HK\$66.2 million, an increase of 3½ times over the same period last year.

Total revenue reached HK\$1,097.6 million, a 19% increase over the first half of last year.

The Board of Directors has not declared any interim dividend for the period under review (2006: Nil).

## Health Sales About HK\$750 Million

Our rapidly growing health-related business achieved sales of HK\$747 million during the interim period. This figure includes the full first half contribution from Vitaquest International Holdings LLC ("Vitaquest"), the largest custom contract nutraceutical manufacturer in the United States, which was acquired in early 2006.

Steady progress was made across our key markets of Hong Kong, the Netherlands, Canada and the United States. In particular, market acceptance of the *AG Natural Health* brand of nutraceutical products has been strong.

### Environmental Sales Over HK\$200 Million

During the first half, sales for the Group's environmental-related business were approximately HK\$211 million. On the whole, satisfactory development was recorded in our main markets throughout Asia, particularly in Malaysia and South Korea, as well as in Australia.

### Major Achievements in R&D

We have continued to devote considerable resources to our R&D initiatives during the period under review and good progress has been recorded.

During the first half of 2007, 14 patents were granted for our pharmaceutical discoveries targeted at cancer treatment, namely:

- 1) kidney cancer;
- 2) prostate cancer;
- 3) ovarian cancer;
- 4) breast cancer;
- 5) uterine cancer;
- 6) leukemia;
- 7) nasopharyngeal cancer;
- 8) esophageal cancer;
- 9) stomach cancer;
- 10) pancreatic cancer;
- 11) liver cancer;
- 12) brain cancer;
- 13) bladder cancer; and
- 14) lymphoma.

Including the above, we have received 42 patents to date from the US Patent and Trademark Office, of which more than half are for the Group's pharmaceutical inventions. Our patent portfolio reflects a growing wealth of intellectual property, particularly in the realm of cancer treatment.

Good progress has been achieved in pharmaceutical research, particularly in skin cancer treatment where our US FDA Phase II trials are progressing very well.

We are also continuing to extend our range of nutraceutical offerings by studying new formulae and developing new product applications for our nutraceutical lines, with the aim of launching them in the market as soon as possible.

### Sound Underlying Financials

With cash and net financial assets on hand amounting to nearly HK\$1.5 billion and bank borrowings of only around HK\$382 million, as at 30 June 2007, the Group remains in an excellent position to fund its growth strategies for the future and drive continued development.

### Subsequent Event

*Earlier this month, CK Life Sciences signed a scheme implementation agreement to acquire Lipa Pharmaceuticals Limited ("Lipa"), the leading Australian contract manufacturer of complementary healthcare products, at a consideration of about HK\$607 million. Subject to the terms of the scheme implementation agreement, the Lipa transaction is expected to be completed in the second half of the year. This proposed acquisition is poised to significantly boost our nutraceutical operations, as well as substantially expedite CK Life Sciences' business expansion plans into the Australian nutraceutical market. This move follows the recent acquisition trail in the nutraceutical sector which saw the Santé Naturelle A.G. Ltée acquisition in 2005 and the Vitaquest one in 2006.*

### Prospects

The first half of 2007 has reaped good results for CK Life Sciences. The Group's sales have reached a critical mass and profit continues to grow. In the near term, we expect our strong sales to maintain its upward trend. This growth will be further boosted through our aggressive acquisition strategy. We are now looking to acquire new nutraceutical, agricultural and biotech companies to further enrich our sales and profit base.

In the medium to long-term, our R&D efforts are expected to mature and bear fruit. We have already achieved significant progress in expanding our patent portfolio, as well as expediting our research studies and clinical trials. We look forward to making more advances in this area and taking our solutions, particularly in the treatment of cancer, through the necessary regulatory procedures.

In sum, CK Life Sciences has achieved a solid track record as a young company. In the five years since listing, CK Life Sciences has evolved into a profitable biotech company. We aim to continue to accelerate the pace of expansion.

### Acknowledgements

I would like to take this opportunity to thank our shareholders, Board of Directors, staff and business partners for their resolute support.

**Li Tzar Kuoi, Victor**

Chairman

Hong Kong, 13 August 2007

## Financial resources and liquidity

As at 30 June 2007, the Group's total assets amounted to HK\$5,975,317,000 of which marketable securities were HK\$1,189,029,000 and total bank balances and cash were HK\$357,597,000. The marketable securities generated a total net investment gain of HK\$76,587,000 while the total bank balances and cash generated a total interest income of HK\$8,286,000 for the first six months of 2007 ("the Period").

At the end of the period under review, the total liabilities were HK\$930,469,000, comprising total bank loans and overdrafts of HK\$381,592,000. These bank loans were raised for financing the acquisition of overseas subsidiaries as well as providing general working capital for some of the overseas subsidiaries. The maturity profiles of these loans vary from 1 to 2 years and incurred a total finance cost of HK\$12,577,000 for the Period. As at 30 June 2007, the Group's gearing ratio was approximately 0.48%, calculated on the basis of the Group's net borrowings (after deducting cash and bank balances of HK\$357,597,000) over total equity. The net asset value of the Group was HK\$0.52 per share.

## Treasury policies

The Group continues to adopt a prudent treasury policy and manage most of its treasury functions at the head office regarding its funding needs, foreign exchange and interest rate exposures.

Most of the Group's financial instruments are denominated in US dollars and thus exchange rate risk relating to such investments is low. For overseas subsidiaries/investments whose assets are non-US dollars, the Group has established a natural hedge with an appropriate level of borrowings in the relevant local currencies in order to mitigate the currency risk.

The Group's borrowings are principally on a floating rate basis. To minimize its interest rate risk under the current uptrend interest rate environment, the Group has been regularly and closely monitoring its overall net debt position, and reviewing its funding costs and loan maturity profile so as to facilitate refinancing at an appropriate time with a lower cost.

## Charge on assets

As at 30 June 2007, the Group's interests in a subsidiary company with the carrying value of HK\$184,486,000 were pledged as part of the security for a bank loan totaling HK\$225,618,000 granted to the subsidiary company.



### Material acquisitions/disposals and significant investments

As detailed in the circular of the Company dated 22 June 2007, a disposal of the Group's equity interests in Nanjing Green Union Eco-Technology Limited ("NJLP"), Jiangsu Technology Union Eco-fertilizer Limited ("Jiangsu Technology") and Jiangsu Prosperous Union Crop Sciences Limited ("JSJB") was completed in the first half of the year. The total consideration of the disposal is RMB53,775,171.8 (approximately HK\$54,850,675). After the disposal, the Group ceased to have any interests in NJLP and JSJB, and the Group's interests in Jiangsu Technology was reduced to 25%.

Other than aforementioned, there were no other material acquisitions/disposals which would have been required to be disclosed under the GEM Listing Rules.

The Group has always been investing significantly in research and development activities. Such investment amounted to about HK\$30,494,000 for the Period.

### Capital commitments and future plans for material investments or capital assets

As of 30 June 2007, the total capital commitments by the Group amounted to HK\$2,740,000 which were mainly made up of contracted commitments in respect of the acquisition of laboratory instrument, computer software, plant and equipment.

### Contingent liabilities

As at 30 June 2007, the Group had no material contingent liabilities.

### Information on employees

The Group had a total number of 1,153 employees at the end of June 2007, a decrease of 207 headcount as compared to the same period of 2006. The total staff costs, including directors' emoluments, amounted to approximately HK\$242,504,000 for the Period. The Group's employment and remuneration policies remained the same as detailed in the Company's annual report for the year ended 31 December 2006.

# Condensed Consolidated Income Statement

	Notes	For the three months ended 30 June		For the six months ended 30 June	
		2007 (unaudited) HK\$'000	2006 (unaudited) HK\$'000	2007 (unaudited) HK\$'000	2006 (unaudited) HK\$'000
Turnover	2	593,817	494,636	1,097,609	922,150
Cost of sales		(392,178)	(290,438)	(723,509)	(554,311)
Other income	3	201,639	204,198	374,100	367,839
Staff costs	4	(1,568)	15,928	4,238	26,889
Depreciation		(75,843)	(69,690)	(144,379)	(125,123)
Amortization of intangible assets		(7,848)	(8,299)	(15,783)	(17,120)
Share of results of associates		(7,608)	(3,924)	(15,295)	(5,449)
Fair value change of investments at fair value through profit and loss/derivative financial instruments		3,353	(39,699)	31,391	(53,706)
Gain on disposal of associates		2,712	–	2,712	–
Gain on disposal of a subsidiary		2,100	–	2,100	–
Other operating expenses		(81,546)	(67,290)	(167,110)	(154,358)
Finance costs		(6,596)	(12,187)	(12,577)	(21,399)
Share of results of associates		(2,033)	812	(3,864)	990
Profit before taxation		26,762	19,849	55,533	18,563
Taxation	5	8,806	3,229	9,937	6,235
Profit for the period		35,568	23,078	65,470	24,798
Attributable to:					
Equity holders of the Company		36,145	12,722	66,248	14,785
Minority interests		(577)	10,356	(778)	10,013
		35,568	23,078	65,470	24,798
Earnings per share	6				
– basic		0.38 cent	0.15 cent	0.69 cent	0.19 cent
– diluted		0.38 cent	0.15 cent	0.69 cent	0.19 cent

# Condensed Consolidated Balance Sheet

	Notes	As at 30 June 2007 (unaudited) HK\$'000	As at 31 December 2006 (audited) HK\$'000
<b>Non-current assets</b>			
Property, plant and equipment	8	350,570	358,180
Prepaid lease for land		12,545	12,700
Intangible assets	9	3,127,721	3,077,477
Interests in associates		21,739	72,909
Available-for-sale investments		154,079	155,727
Investments at fair value through profit and loss		965,185	920,265
Deferred taxation		41,808	19,178
		<b>4,673,647</b>	<b>4,616,436</b>
<b>Current assets</b>			
Investments at fair value through profit and loss		53,634	12,709
Derivative financial instruments		16,131	19,544
Inventories		342,798	320,489
Receivables and prepayments	10	531,510	502,852
Deposit with financial institution		47,931	47,931
Bank balances and deposits		309,666	411,693
		<b>1,301,670</b>	<b>1,315,218</b>
<b>Current liabilities</b>			
Payables and accruals	10	(316,264)	(438,286)
Derivative financial instruments		(90,443)	(63,630)
Bank overdrafts		(31,662)	–
Bank loans	11	(225,618)	–
Finance lease obligations		(1,175)	(2,222)
Taxation		(13,199)	(16,057)
		<b>(678,361)</b>	<b>(520,195)</b>
<b>Net current assets</b>		<b>623,309</b>	<b>795,023</b>
<b>Total assets less current liabilities</b>		<b>5,296,956</b>	<b>5,411,459</b>

# Condensed Consolidated Balance Sheet (cont'd)

	Notes	As at 30 June 2007 (unaudited) HK\$'000	As at 31 December 2006 (audited) HK\$'000
<b>Non-current liabilities</b>			
Bank loans	11	(124,312)	(322,877)
Finance lease obligations		(1,191)	(1,505)
Loan from a minority shareholder		(24,711)	(23,828)
Deferred taxation		(101,894)	(101,225)
		(252,108)	(449,435)
<b>Total net assets</b>		<b>5,044,848</b>	<b>4,962,024</b>
<b>Capital and reserves</b>			
Share capital	12	961,107	961,107
Share premium and reserves		4,076,610	3,985,346
<b>Equity attributable to equity holders of the Company</b>		<b>5,037,717</b>	<b>4,946,453</b>
<b>Minority interests</b>		<b>7,131</b>	<b>15,571</b>
<b>Total equity</b>		<b>5,044,848</b>	<b>4,962,024</b>

# Consolidated Statement of Changes in Equity

	Share capital (unaudited) HK\$'000	Share premium (unaudited) HK\$'000	Investment revaluation reserve (unaudited) HK\$'000	Exchange reserve (unaudited) HK\$'000	Employee share-based reserve (unaudited) HK\$'000	Accumulated losses (unaudited) HK\$'000	Equity attributable to equity holders of the Company (unaudited) HK\$'000	Minority interest (unaudited) HK\$'000	Total equity (unaudited) HK\$'000
<b>2006</b>									
At 1 January 2006	640,738	2,392,185	(27,602)	(35)	8,186	(277,212)	2,736,260	47,827	2,784,087
Loss on fair value changes of available-for-sale-investments	-	-	(6,764)	-	-	-	(6,764)	-	(6,764)
Employees' share options benefits	-	-	-	-	260	-	260	-	260
Exchange difference on translation of financial statements of overseas operations	-	-	-	14,298	-	-	14,298	-	14,298
Shares issued under rights issue	320,369	1,762,030	-	-	-	-	2,082,399	-	2,082,399
Transaction costs arising from rights issue	-	(6,696)	-	-	-	-	(6,696)	-	(6,696)
Arising from acquisition of additional interest in subsidiaries	-	-	-	-	-	-	-	(1,709)	(1,709)
Arising from acquisition of subsidiaries	-	-	-	-	-	-	-	193	193
Profit for the period	-	-	-	-	-	14,785	14,785	10,013	24,798
At 30 June 2006	961,107	4,147,519	(34,366)	14,263	8,446	(262,427)	4,834,542	56,324	4,890,866
<b>2007</b>									
At 1 January 2007	961,107	4,147,543	(22,945)	27,226	8,712	(175,190)	4,946,453	15,571	4,962,024
Loss on fair value changes of available-for-sale-investments	-	-	(1,648)	-	-	-	(1,648)	-	(1,648)
Employees' share options lapsed during the period	-	-	-	-	(1,141)	1,141	-	-	-
Release on disposal of a subsidiary	-	-	-	(912)	-	-	(912)	(7,662)	(8,574)
Release on disposal of associates	-	-	-	(3,628)	-	-	(3,628)	-	(3,628)
Exchange difference on translation of financial statements of overseas operations	-	-	-	31,204	-	-	31,204	-	31,204
Profit for the period	-	-	-	-	-	66,248	66,248	(778)	65,470
At 30 June 2007	961,107	4,147,543	(24,593)	53,890	7,571	(107,801)	5,037,717	7,131	5,044,848

# Condensed Consolidated Cash Flow Statement

	For the six months ended 30 June	
	2007 (unaudited) HK\$'000	2006 (unaudited) HK\$'000
Net cash used in operating activities	(67,102)	(112,325)
Net cash outflow from investing activities	(52,832)	(2,006,029)
Net cash inflow from financing activities	17,907	2,065,400
Decrease in cash and cash equivalents	(102,027)	(52,954)
Cash and cash equivalents at beginning of the period	411,693	411,433
Cash and cash equivalents at end of the period	309,666	358,479

## 1. Basis of preparation

The unaudited condensed consolidated financial statements have been prepared in accordance with the Hong Kong Accounting Standards 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants and the applicable disclosure requirements of the GEM Listing Rules. They have also been prepared under the historical cost convention, except for certain properties and financial instruments which are measured at revaluated amounts or fair values.

The accounting policies used in preparing the interim financial statements are consistent with those used in the Group's annual financial statements for the year ended 31 December 2006.

## 2. Turnover and segment information

Turnover represents the net invoiced value of goods sold, after allowance for returns and trade discount as well as income from investment, and is analysed as follows:

### A. Segment turnover

An analysis of the business segment turnover is as follows:

	<b>For the six months ended 30 June</b>	
	<b>2007</b>	2006
	<b>HK\$'000</b>	HK\$'000
Environment	<b>210,587</b>	251,042
Health	<b>747,497</b>	617,355
Investment income	<b>139,525</b>	53,753
	<b>1,097,609</b>	922,150

**B. Segment results**

An analysis of the business segment results is as follows:

	<b>For the six months ended 30 June</b>	
	<b>2007 HK\$'000</b>	2006 HK\$'000
Environment	<b>(1,954)</b>	(1,993)
Health	<b>35,436</b>	80,490
Investment	<b>81,861</b>	18,149
	<b>115,343</b>	96,646
Business development expenditure	<b>(15,588)</b>	(22,607)
Research and development expenditure	<b>(13,011)</b>	(14,490)
Corporate expenses	<b>(19,583)</b>	(20,577)
Gain on disposal of associates	<b>2,712</b>	–
Gain on disposal of a subsidiary	<b>2,100</b>	–
Finance costs	<b>(12,577)</b>	(21,399)
Share of results of associates	<b>(3,863)</b>	990
Profit before taxation	<b>55,533</b>	18,563
Taxation	<b>9,937</b>	6,235
Profit for the period	<b>65,470</b>	24,798

**3. Other income**

Other revenue mainly comprises income from bank deposits and gain/(loss) on disposal of financial instruments.



#### 4. Staff costs

Staff costs which include salaries, bonuses, equity-settled share-based payment, retirement benefit scheme contribution and recruitment costs for the three months and six months ended 30 June 2007 respectively amounted to HK\$121,492,000 (2006: HK\$139,337,000) and HK\$242,504,000 (2006: HK\$207,056,000) of which HK\$3,569,000 (2006: HK\$5,689,000) and HK\$8,255,000 (2006: HK\$11,284,000) relating to development activities were capitalized and HK\$42,080,000 (2006: HK\$63,958,000) and HK\$89,870,000 (2006: HK\$70,649,000) were allocated to costs of sales.

#### 5. Taxation

	For the six months ended 30 June	
	2007 HK\$'000	2006 HK\$'000
Current tax:		
Hong Kong	3,312	–
Other jurisdictions	1,572	687
Deferred tax:	–	–
Hong Kong	215	–
Other jurisdictions	(15,036)	(6,922)
	<b>(9,937)</b>	<b>(6,235)</b>

Hong Kong profits tax has been provided at the rate of 17.5%. Taxation arising in other jurisdictions is calculated at the rates prevailing in the relevant jurisdictions.

## 6. Earnings per share

The calculations of the basic and diluted earnings per share are based on the following data:

	For the three months ended 30 June		For the six months ended 30 June	
	2007 HK\$'000	2006 HK\$'000	2007 HK\$'000	2006 HK\$'000
<b>Profit for the period</b>				
Profit for calculating basic and diluted earnings per share	36,145	12,722	66,248	14,785
<b>Number of shares</b>				
Weighted average number of ordinary shares used in the calculation of basic and diluted earnings per share	9,611,072,400	8,578,568,622	9,611,072,400	7,894,035,731

The weighted average numbers of ordinary shares used in the calculation of earnings per share for the three months and six months ended 30 June 2006 have accounted for the issuance of new shares pursuant to the rights issue which was completed on 10 May 2006.

The computation of diluted earnings per share does not assume the exercise of the Company's outstanding share options for the three months and six months ended 30 June 2007.

## 7. Dividend

The Board of Directors of the Company has not declared an interim dividend for the six months ended 30 June 2007 (2006: Nil).

## 8. Property, plant and equipment

	Freehold land and building HK\$'000	Construction in progress HK\$'000	Laboratory instruments, plant and equipment HK\$'000	Furniture, fixtures and other assets HK\$'000	Leasehold improvement HK\$'000	Total HK\$'000
Cost or valuation						
At 1 January 2007	103,160	1,497	303,904	82,815	46,261	537,637
Net additions	480	279	17,716	2,707	2,638	23,820
Disposal of a subsidiary	–	(56)	–	(79)	–	(135)
<b>At 30 June 2007</b>	<b>103,640</b>	<b>1,720</b>	<b>321,620</b>	<b>85,443</b>	<b>48,899</b>	<b>561,322</b>
Accumulated depreciation						
At 1 January 2007	9,572	–	113,942	48,839	7,104	179,457
Provided for the period	1,546	–	20,985	6,543	2,281	31,355
Disposal of a subsidiary	–	–	–	(60)	–	(60)
<b>At 30 June 2007</b>	<b>11,118</b>	<b>–</b>	<b>134,927</b>	<b>55,322</b>	<b>9,385</b>	<b>210,752</b>
Net book value						
<b>At 30 June 2007</b>	<b>92,522</b>	<b>1,720</b>	<b>186,693</b>	<b>30,121</b>	<b>39,514</b>	<b>350,570</b>
At 31 December 2006	93,588	1,497	189,962	33,976	39,157	358,180

## 9. Intangible assets

	Development costs	Patents	Goodwill	Trade-mark	Customer relationship	Distribution network	Other intangible assets	Total
	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Cost								
At 1 January 2007	248,408	14,342	2,482,526	110,592	209,539	37,463	7,936	3,110,806
Net additions	17,584	1,168	35,751	7,769	2,098	-	1,749	66,119
<b>At 30 June 2007</b>	<b>265,992</b>	<b>15,510</b>	<b>2,518,277</b>	<b>118,361</b>	<b>211,637</b>	<b>37,463</b>	<b>9,685</b>	<b>3,176,925</b>
Amortization								
At 1 January 2007	11,813	1,710	-	-	16,010	2,205	1,591	33,329
Provided for the period	1,674	207	-	-	11,128	1,941	925	15,875
<b>At 30 June 2007</b>	<b>13,487</b>	<b>1,917</b>	<b>-</b>	<b>-</b>	<b>27,138</b>	<b>4,146</b>	<b>2,516</b>	<b>49,204</b>
Net book value								
<b>At 30 June 2007</b>	<b>252,505</b>	<b>13,593</b>	<b>2,518,277</b>	<b>118,361</b>	<b>184,499</b>	<b>33,317</b>	<b>7,169</b>	<b>3,127,721</b>
At 31 December 2006	236,595	12,632	2,482,526	110,592	193,529	35,258	6,345	3,077,477

## 10. Receivables and payables

The Group has a policy of allowing an average credit period of 90 days to its customers. Aging analyses of trade debtors and trade creditors are as follows:

	<b>As at 30 June 2007 HK\$'000</b>	As at 31 December 2006 HK\$'000
<b>Trade debtors</b>		
0 – 90 days	292,968	359,183
> 90 days	38,376	32,297
	<b>331,344</b>	391,480
<b>Trade creditors</b>		
0 – 90 days	157,455	249,469
> 90 days	24,234	40,285
	<b>181,689</b>	289,754

## 11. Bank loans

Certain bank loans are secured by a charge over the assets of a subsidiary company.

**12. Share capital**

	<b>Number of shares of HK\$0.10 each '000</b>	<b>Nominal value HK\$'000</b>
<b>Authorized</b>		
At 31 December 2006 and 30 June 2007	15,000,000	1,500,000
<b>Issued and fully paid</b>		
At 31 December 2006 and 30 June 2007	9,611,073	961,107

**13. Related party transactions**

During the six months ended 30 June 2007, the Group entered into the following transactions with related parties:

- a) The Group made sales of HK\$11,082,000 (2006: HK\$5,297,000) to Hutchison International Limited ("HIL") group. HIL is a wholly-owned subsidiary of Hutchison Whampoa Limited which is the associate of a substantial shareholder of the Company, Cheung Kong (Holdings) Limited.
- b) The Group leased certain properties from Leknarf Associates, LLC ("Leknarf") which is an associate of a minority shareholder of a non-wholly owned subsidiary company, Vitaquest International Holdings LLC ("Vitaquest"). The total rental payment by the Group to Leknarf amounted to HK\$7,534,000 in 2007 (2006: HK\$6,196,000). Included in receivables and prepayments is prepaid rental amounted to HK\$355,000 (2006: HK\$225,000) to Leknarf.
- c) The Group was the manufacturer and supplier of the dietary supplement, food and cosmetic lines of products for Nu-Life Corp. ("Nu-Life"). Nu-Life is controlled by a substantial shareholder of Vitaquest and is a connected person of the Group. The sales made by the Group to Nu-Life amounted to HK\$3,454,000 in 2007 (2006: HK\$11,583,000). The outstanding balance due from Nu-Life at the period ended date amounted to HK\$1,280,000 (2006: HK\$7,497,000).

# Directors' Interests and Short Positions in Shares, Underlying Shares and Debentures

As at 30 June 2007, the interests or short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")) which were notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company under Section 352 of the SFO, or which were required, pursuant to the Model Code on Securities Transactions by Directors adopted by the Company ("Model Code"), to be notified to the Company and the Stock Exchange, were as follows:

## (1) Long positions in the shares of the Company

Name of Director	Capacity	Number of Ordinary Shares				Total	Approximate % of Shareholding
		Personal Interests	Family Interests	Corporate Interests	Other Interests		
Li Tzar Kuoi, Victor	Beneficial owner & beneficiary of trusts	2,250,000	-	-	4,258,634,570 (Note)	4,260,884,570	44.33%
Kam Hing Lam	Interest of child or spouse	-	6,225,000	-	-	6,225,000	0.06%
Ip Tak Chuen, Edmond	Beneficial owner	2,250,000	-	-	-	2,250,000	0.02%
Yu Ying Choi, Alan Abel	Beneficial owner	2,250,000	-	-	-	2,250,000	0.02%
Chu Kee Hung	Beneficial owner	2,250,000	-	-	-	2,250,000	0.02%
Peter Peace Tulloch	Beneficial owner	1,050,000	-	-	-	1,050,000	0.01%
Wong Yue-chim, Richard	Beneficial owner	375,000	-	-	-	375,000	0.004%
Kwok Eva Lee	Beneficial owner	200,000	-	-	-	200,000	0.002%

## Directors' Interests and Short Positions in Shares, Underlying Shares and Debentures (cont'd)

Note:

Such 4,258,634,570 shares are held by a subsidiary of Cheung Kong (Holdings) Limited ("Cheung Kong Holdings"). Li Ka-Shing Unity Trustee Company Limited ("TUT") as trustee of The Li Ka-Shing Unity Trust (the "LKS Unity Trust") and companies controlled by TUT as trustee of the LKS Unity Trust hold more than one-third of the issued share capital of Cheung Kong Holdings. Li Ka-Shing Unity Trustee Corporation Limited ("TDT1") as trustee of The Li Ka-Shing Unity Discretionary Trust ("DT1") and Li Ka-Shing Unity Trustcorp Limited ("TDT2") as trustee of another discretionary trust ("DT2") hold all issued and outstanding units in the LKS Unity Trust but are not entitled to any interest or share in any particular property comprising the trust assets of the LKS Unity Trust. The discretionary beneficiaries of such discretionary trusts are, inter alia, Mr. Li Tzar Kuoi, Victor, his wife and children, and Mr. Li Tzar Kai, Richard. Mr. Li Tzar Kuoi, Victor, as a discretionary beneficiary of such discretionary trusts and a Director of the Company, is taken to be interested in those shares of Cheung Kong Holdings and thus is taken to be interested in those 4,258,634,570 shares held by the subsidiary of Cheung Kong Holdings under the SFO.



## Directors' Interests and Short Positions in Shares, Underlying Shares and Debentures (cont'd)

### (2) Long positions in the underlying shares of the Company

Pursuant to the share option scheme adopted by the Company on 26 June 2002 (the "Share Option Scheme"), certain Directors in the capacity as beneficial owners were granted unlisted and physically settled share options to subscribe for shares of the Company, details of which as at 30 June 2007 were as follows:

Name of Director	Date of grant	Number of share options				Outstanding as at 30 June 2007	Option period	Subscription price per share HK\$
		Outstanding as at 1 January 2007	Granted during the period	Exercised during the period	Cancelled/ lapsed during the period			
Yu Ying Choi,	30/9/2002	348,440	-	-	-	348,440	30/9/2003 - 29/9/2012	1.422
Alan Abel	27/1/2003	775,560	-	-	-	775,560	27/1/2004 - 26/1/2013	1.286
	19/1/2004	775,560	-	-	-	775,560	19/1/2005 - 18/1/2014	1.568
Chu Kee Hung	30/9/2002	348,440	-	-	-	348,440	30/9/2003 - 29/9/2012	1.422
	27/1/2003	775,560	-	-	-	775,560	27/1/2004 - 26/1/2013	1.286
	19/1/2004	775,560	-	-	-	775,560	19/1/2005 - 18/1/2014	1.568

Save as disclosed above, during the six months ended 30 June 2007, none of the Directors or their respective associates was granted share options to subscribe for shares of the Company, nor had exercised such rights.

Save as disclosed above, none of the Directors or chief executive of the Company had, as at 30 June 2007, any interests or short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company under Section 352 of the SFO, or which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

# Details of Options Granted by the Company

The Company has adopted the Share Option Scheme under which the Directors or employees of the Company or its subsidiaries or certain other persons may be granted share options to subscribe for shares of the Company subject to the terms and conditions stipulated in the Share Option Scheme.

As at 30 June 2007, options to subscribe for an aggregate of 15,109,593 shares of the Company granted to certain continuous contract employees (including the Executive Directors of the Company as disclosed above) pursuant to the Share Option Scheme were outstanding, details of which were as follows:

Date of grant	Number of share options					Outstanding as at 30 June 2007	Option period	Subscription price per share HK\$
	Outstanding as at 1 January 2007	Granted during the period	Exercised during the period	Lapsed during the period	Cancelled during the period			
30/9/2002	2,869,010	-	-	(200,072)	-	2,668,938	30/9/2003 – 29/9/2012 (Note 1)	1.422
27/1/2003	6,294,623	-	-	(494,560)	-	5,800,063	27/1/2004 – 26/1/2013 (Note 2)	1.286
19/1/2004	7,279,024	-	-	(638,432)	-	6,640,592	19/1/2005 – 18/1/2014 (Note 3)	1.568

Notes:

1. The options are exercisable from 30 September 2003 to 29 September 2012 (both days inclusive) subject to the following vesting periods:
  - (i) up to 35% of the options commencing on 30 September 2003;
  - (ii) up to 70% of the options (including the options not exercised under the limit prescribed for in the previous period) commencing on 30 September 2004; and
  - (iii) up to 100% of the options (including the options not exercised under the limit prescribed for in the previous periods) commencing on 30 September 2005.

2. The options are exercisable from 27 January 2004 to 26 January 2013 (both days inclusive) subject to the following vesting periods:
  - (i) up to 35% of the options commencing on 27 January 2004;
  - (ii) up to 70% of the options (including the options not exercised under the limit prescribed for in the previous period) commencing on 27 January 2005; and
  - (iii) up to 100% of the options (including the options not exercised under the limit prescribed for in the previous periods) commencing on 27 January 2006.
3. The options are exercisable from 19 January 2005 to 18 January 2014 (both days inclusive) subject to the following vesting periods:
  - (i) up to 35% of the options commencing on 19 January 2005;
  - (ii) up to 70% of the options (including the options not exercised under the limit prescribed for in the previous period) commencing on 19 January 2006; and
  - (iii) up to 100% of the options (including the options not exercised under the limit prescribed for in the previous periods) commencing on 19 January 2007.

# Interests and Short Positions of Shareholders

So far as is known to any Director or chief executive of the Company, as at 30 June 2007, shareholders (other than Directors or chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO or were otherwise notified to the Company were as follows:

## (1) Long positions of substantial shareholders in the shares of the Company

Name	Capacity	Number of Ordinary Shares	Approximate % of Shareholding
Gold Rainbow Int'l Limited	Beneficial owner	4,258,634,570	44.30%
Gotak Limited	Interest of a controlled corporation	4,258,634,570 (Note i)	44.30%
Cheung Kong (Holdings) Limited	Interest of controlled corporations	4,258,634,570 (Note ii)	44.30%
Li Ka-Shing Unity Trustee Company Limited as trustee of The Li Ka-Shing Unity Trust	Trustee	4,258,634,570 (Note iii)	44.30%
Li Ka-Shing Unity Trustee Corporation Limited as trustee of The Li Ka-Shing Unity Discretionary Trust	Trustee & beneficiary of a trust	4,258,634,570 (Note iii)	44.30%
Li Ka-Shing Unity Trustcorp Limited as trustee of another discretionary trust	Trustee & beneficiary of a trust	4,258,634,570 (Note iii)	44.30%
Li Ka-shing	Founder of discretionary trusts & interest of controlled corporations	4,258,634,570 (Note iv)	44.30%
Trueway International Limited	Beneficial owner	2,119,318,286	22.05%
Li Ka Shing Foundation Limited	Interest of controlled corporations	2,835,759,715 (Note v)	29.50%

### (2) Long position of other person in the shares of the Company

Name	Capacity	Number of Ordinary Shares	Approximate % of Shareholding
Triluck Assets Limited	Beneficial owner	716,441,429	7.45%

Notes:

- i. This represents the same block of shares in the Company as shown against the name of Gold Rainbow Int'l Limited ("Gold Rainbow") above. Since Gold Rainbow is wholly-owned by Gotak Limited, Gotak Limited is deemed to be interested in the same number of shares in which Gold Rainbow was interested under the SFO.
- ii. As Gotak Limited is wholly-owned by Cheung Kong Holdings, Cheung Kong Holdings is deemed to be interested in the same number of shares which Gotak Limited is deemed to be interested under the SFO.
- iii. TUT as trustee of the LKS Unity Trust and companies controlled by TUT as trustee of the LKS Unity Trust hold more than one-third of the issued share capital of Cheung Kong Holdings. TDT1 as trustee of DT1 and TDT2 as trustee of DT2 hold all issued and outstanding units in the LKS Unity Trust but are not entitled to any interest or share in any particular property comprising the trust assets of the LKS Unity Trust. Under the SFO, each of TUT as trustee of the LKS Unity Trust, TDT1 as trustee of DT1 and TDT2 as trustee of DT2 is deemed to be interested in the same block of shares as Cheung Kong Holdings is deemed to be interested as disclosed in Note ii above.
- iv. As Mr. Li Ka-shing owns one-third of the issued share capital of Li Ka-Shing Unity Holdings Limited which in turn holds the entire issued share capital of TUT, TDT1 and TDT2 and is the settlor and may be regarded as a founder of each of DT1 and DT2 for the purpose of the SFO, Mr. Li Ka-shing is deemed to be interested in the same number of shares in which Cheung Kong Holdings is deemed to be interested as mentioned above under the SFO.
- v. Trueway International Limited ("Trueway") and Triluck Assets Limited ("Triluck") are wholly-owned by Li Ka Shing Foundation Limited ("LKSF") and LKSF is deemed to be interested in a total of 2,835,759,715 shares under the SFO, being the aggregate of the shares in which Trueway and Triluck were interested as shown against the names Trueway and Triluck above.

Save as disclosed above, as at 30 June 2007, the Company has not been notified by any persons (other than Directors or chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

# Competing Interests

During the six months ended 30 June 2007, the interests of Directors, management shareholders of the Company or their respective associates as defined in the GEM Listing Rules (the "Associates") in the businesses which compete or may compete, either directly or indirectly, with the businesses of the Group (the "Competing Business") as required to be disclosed pursuant to the GEM Listing Rules were as follows:

## (1) Core business activities of the Group

- (i) Research and development, manufacturing, commercialization, marketing and selling of environmental and human health products.
- (ii) Investment in various financial and investment products.

## (2) Interests in Competing Business

Name of Director	Name of Company	Nature of Interest	Competing Business (Note 2)
Li Tzar Kuoi, Victor	Cheung Kong (Holdings) Limited	Managing Director and Deputy Chairman (Note 1)	(ii)
	Hutchison Whampoa Limited	Executive Director and Deputy Chairman (Note 1)	(i) & (ii)
	Cheung Kong Infrastructure Holdings Limited	Chairman (Note 1)	(i) & (ii)
	Hongkong Electric Holdings Limited	Executive Director (Note 1)	(ii)
Kam Hing Lam	Cheung Kong (Holdings) Limited	Deputy Managing Director (Note 1)	(ii)
	Hutchison Whampoa Limited	Executive Director (Note 1)	(i) & (ii)
	Cheung Kong Infrastructure Holdings Limited	Group Managing Director (Note 1)	(i) & (ii)
	Hongkong Electric Holdings Limited	Executive Director	(ii)

Name of Director	Name of Company	Nature of Interest	Competing Business (Note 2)
Ip Tak Chuen, Edmond	Cheung Kong (Holdings) Limited	Deputy Managing Director	(ii)
	Cheung Kong Infrastructure Holdings Limited	Executive Director and Deputy Chairman	(i) & (ii)
	TOM Group Limited	Non-executive Director	(ii)
	CATIC International Holdings Limited	Non-executive Director	(ii)
	Excel Technology International Holdings Limited	Non-executive Director	(ii)
	Shougang Concord International Enterprises Company Limited	Non-executive Director	(ii)
	The Ming An (Holdings) Company Limited	Non-executive Director	(ii)
Wong Yue-chim, Richard	Great Eagle Holdings Limited	Independent Non-executive Director	(ii)
	Orient Overseas (International) Limited	Independent Non-executive Director	(ii)
Kwok Eva Lee	Cheung Kong Infrastructure Holdings Limited	Independent Non-executive Director	(i) & (ii)
Colin Stevens Russel	Cheung Kong Infrastructure Holdings Limited	Independent Non-executive Director	(i) & (ii)

## Competing Interests (cont'd)

Name of Management Shareholder	Name of Company	Nature of Interest	Competing Business (Note 2)
Li Ka-shing	Cheung Kong (Holdings) Limited	Chairman (Note 1)	(ii)
	Hutchison Whampoa Limited	Chairman (Note 1)	(i) & (ii)

Notes:

1. Apart from holding the directorships, Mr. Li Ka-shing, Mr. Li Tzar Kuoi, Victor and Mr. Kam Hing Lam and/or their respective family members have direct and/or indirect interests in the shares of such companies where appropriate.
2. Such businesses may be made through subsidiaries, associated companies or by way of other forms of investments.

Save as disclosed above, none of the Directors, the management shareholders of the Company or their respective Associates have any interests in a business which competes or may compete, either directly or indirectly, with the businesses of the Group.



## Corporate Governance

The Board of Directors (“Board”) and the management of the Company are committed to the maintenance of good corporate governance practices and procedures. The corporate governance principles of the Company emphasize a quality Board, sound internal controls, and transparency and accountability to all shareholders. The Company has applied the principles and complied with all code provisions and, where applicable, the recommended best practices of the Code on Corporate Governance Practices (“Code on CG Practices”) as set out in Appendix 15 of the GEM Listing Rules throughout the six months ended 30 June 2007.

### (1) Board Composition and Board Practices

The Board is collectively responsible for the oversight of the management of the business and affairs of the Group with the objective of enhancing shareholders value. The Board consists of a total of nine Directors, comprising five Executive Directors, one Non-executive Director and three Independent Non-executive Directors. One-third of the Board are Independent Non-executive Directors and at least one of them has appropriate professional qualifications, or accounting or related financial management expertise as required by the GEM Listing Rules. All Directors (including Non-executive Directors) are subject to retirement by rotation once every three years in accordance with the Company’s Articles of Association and the Code on CG Practices.

The positions of the Chairman of the Board (“Chairman”) and the Chief Executive Officer are held by separate individuals with a view to maintaining an effective segregation of duties respecting management of the Board and the day-to-day management of the Group’s business.

All Directors have made active contribution to the affairs of the Board and the Board has always acted in the best interests of the Group. In addition to regular Board meetings, the Chairman has meetings with the Non-executive Directors (including the Independent Non-executive Directors) without the presence of Executive Directors at least once every year.

The Company Secretary is responsible to the Board for ensuring that Board procedures are followed and for ensuring that the Board is briefed on all legislative, regulatory and corporate governance developments and that the Board has regard to them when making decisions. The Company Secretary and the Compliance Officer are also directly responsible for the Group's compliance with the continuing obligations of the GEM Listing Rules, Codes on Takeovers and Mergers and Share Repurchases, Companies Ordinance, SFO and other applicable laws, rules and regulations.

### **(2) Model Code on Securities Transactions by Directors**

The Company has adopted the model code on securities transactions by directors of listed issuers set out in Chapter 5 of the GEM Listing Rules as its own code of conduct regarding Directors' securities transactions, effective 31 March 2004. Confirmation has been received from all Directors that they have complied with the required standards set out in the Model Code during the six months ended 30 June 2007.

### **(3) Internal Controls**

The Company has an internal audit function in place to provide an independent assessment of the Group's internal control system and review of its effectiveness in accordance with the Code on CG Practices. The Internal Audit Department prepares its audit plan using a risk based methodology in consultation with, but independent of, the management for review by the audit committee of the Company ("Audit Committee"). The audit work focuses on financial, functional and information technology areas within the audited business units and those areas of the Group's activities with significant perceived risks. An integral part of the internal audit function is to monitor and ensure effective implementation of these internal control systems.

The Board, through the Audit Committee, has conducted a review of the effectiveness of internal control system operating in the Group for the six months ended 30 June 2007.

#### (4) Audit Committee

The Company established the Audit Committee on 26 June 2002 and has formulated its written terms of reference in accordance with the provisions set out in the Code on CG Practices. The existing Audit Committee comprises three Independent Non-executive Directors, namely, Professor Wong Yue-chim, Richard (Chairman of the Audit Committee), Mrs. Kwok Eva Lee and Mr. Colin Stevens Russel. The principal duties of the Audit Committee include the review and supervision of the Group's financial reporting system and internal control procedures, review of the Group's financial information and review of the relationship with the external auditors of the Company.

The Group's half-year report for the six months ended 30 June 2007 has been reviewed by the Audit Committee.

#### (5) Remuneration Committee

According to the Code on CG Practices, the Company established its remuneration committee ("Remuneration Committee") on 1 January 2005 with a majority of the members being Independent Non-executive Directors. The existing Remuneration Committee comprises the Chairman of the Board, Mr. Li Tzar Kuoi, Victor (Chairman of the Remuneration Committee), and two Independent Non-executive Directors, namely, Mrs. Kwok Eva Lee and Mr. Colin Stevens Russel.

The principal responsibilities of the Remuneration Committee include making recommendations to the Board on the Company's policy and structure for the remuneration of Directors and senior management, and reviewing the specific remuneration packages of all Executive Directors and senior management by reference to corporate goals and objectives resolved by the Board from time to time.

### **(6) Investor Relations and Communication with Shareholders**

The Company establishes different communication channels with shareholders and investors, including (i) printed copies of financial reports, circulars, notices of general meetings and proxy forms required under the GEM Listing Rules, and shareholders can select to receive such documents by electronic means; (ii) the annual general meeting provides a forum for shareholders to raise comments and exchange views with the Board; (iii) updated and key information of the Group is available on the website of the Company; (iv) the Company's website offers a main communication channel between the Company and its shareholders and investors; (v) regular press conferences and briefing meetings with analysts from the investment sectors are set up from time to time on updated performance information of the Group; (vi) the Company's Branch Share Registrar deals with shareholders for share registration matters; and (vii) Corporate Affairs Department of the Company handles enquiries from shareholders and investors generally.

### **Purchase, Sale or Redemption of the Company's Listed Securities**

During the six months ended 30 June 2007, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities.

## Board of Directors

### Executive Directors

LI Tzar Kuoi, Victor

*Chairman*

KAM Hing Lam

*President and Chief Executive Officer*

IP Tak Chuen, Edmond

*Senior Vice President and*

*Chief Investment Officer*

YU Ying Choi, Alan Abel

*Vice President and Chief Operating Officer*

CHU Kee Hung

*Vice President and Chief Scientific Officer*

### Non-executive Directors

Peter Peace TULLOCH

*Non-executive Director*

WONG Yue-chim, Richard

*Independent Non-executive Director*

KWOK Eva Lee

*Independent Non-executive Director*

Colin Stevens RUSSEL

*Independent Non-executive Director*

## Audit Committee

WONG Yue-chim, Richard

*Chairman*

KWOK Eva Lee

Colin Stevens RUSSEL

## Remuneration Committee

LI Tzar Kuoi, Victor

*Chairman*

KWOK Eva Lee

Colin Stevens RUSSEL

## Company Secretary

Eirene YEUNG

## Qualified Accountant

MO Yiu Leung, Jerry

## Compliance Officer

YU Ying Choi, Alan Abel

## Authorized Representatives

IP Tak Chuen, Edmond

Eirene YEUNG

## Auditors

Deloitte Touche Tohmatsu

## Principal Bankers

The Hongkong and Shanghai Banking Corporation Limited  
JP Morgan Chase Bank, N.A.  
Canadian Imperial Bank of Commerce  
Commonwealth Bank of Australia  
Citibank, N.A.

## Legal Advisers

Woo, Kwan, Lee & Lo  
Dibb Lupton Alsop

## Registered Office

P.O. Box 309GT  
Ugland House  
South Church Street  
Grand Cayman  
Cayman Islands

## Head Office

2 Dai Fu Street  
Tai Po Industrial Estate  
Tai Po  
Hong Kong

## Principal Place of Business

7th Floor, Cheung Kong Center  
2 Queen's Road Central  
Hong Kong

## Principal Share Registrar and Transfer Office

Butterfield Fund Services (Cayman) Limited  
Butterfield House  
68 Fort Street, P.O. Box 705  
George Town  
Grand Cayman  
Cayman Islands

## Branch Share Registrar and Transfer Office

Computershare Hong Kong Investor Services Limited  
Rooms 1712 – 1716, 17th Floor  
Hopewell Centre  
183 Queen's Road East, Hong Kong

## Stock Codes

The Stock Exchange of Hong Kong Limited: 8222  
Bloomberg: 8222 HK  
Reuters: 8222.HK

## Website

<http://www.ck-lifesciences.com>

## Key Date

Half-year Results Announcement 13.8.2007